An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Repare Therapeutics Inc. (NASDAQ: RPTX) has announced participation at two upcoming investor conferences in November 2022. The first is the H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference on November 14 at 10:00 a.m. ET. The second is the Piper Sandler 34th Annual Healthcare Conference on November 29 at 3:00 p.m. ET, taking place in New York, NY. Investors can access live webcasts of both events on the Company’s website, with replays available for 90 days. Repare focuses on precision oncology and utilizes its proprietary SNIPRx® platform for novel cancer therapies.
Positive
None.
Negative
None.
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in November. Details for the fireside chats are as follows:
H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference Date: Monday, November 14, 2022 Time: 10:00 a.m. Eastern Time Location: Virtual
Piper Sandler 34th Annual Healthcare Conference
Date: Tuesday, November 29, 2022 Time: 3:00 p.m. Eastern Time Location: New York, NY
A live webcast of the fireside chats can be accessed in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events. A replay of the webcasts will be archived on the Company’s website for at least 90 days.
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development; camonsertib (also known as RP-3500), a potential leading ATR inhibitor currently in Phase 1/2 clinical development partnered with Roche; RP-2119, a Polθ inhibitor program in ongoing IND-enabling studies; as well as several additional, undisclosed preclinical programs. For more information, please visit reparerx.com.
SNIPRx® is a registered trademark of Repare Therapeutics Inc.
What conferences will Repare Therapeutics attend in November 2022?
Repare Therapeutics will attend the H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference on November 14 and the Piper Sandler 34th Annual Healthcare Conference on November 29.
What is the date and time of the H.C. Wainwright Conference?
The H.C. Wainwright Conference will take place on November 14, 2022, at 10:00 a.m. Eastern Time.
Where will the Piper Sandler Conference be held?
The Piper Sandler Conference will be held in New York, NY, on November 29, 2022, at 3:00 p.m. Eastern Time.
How can I watch the Repare Therapeutics conference presentations?
You can access live webcasts of the presentations on Repare Therapeutics' Investor Relations website, with replays available for at least 90 days.
What is Repare Therapeutics known for?
Repare Therapeutics is known for its precision oncology approach and its proprietary SNIPRx® platform to develop targeted cancer therapies.
